| Quantity | 100 μg | 100 μg | 5 slides | 20 nmol, 50 nmol, 100 nmol, 200 nmol | 20 nmol, 50 nmol, 100 nmol, 200 nmol |
| Description | This product GTTS-WK4010MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the CD52 protein. This product can be used in -related researches. | This product GTTS-WK5890MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the IL-4 protein. This product can be used in -related researches. | Creative Biolabs' Neuropathy Frozen Tissue Panels are designed for the study of Alzheimer's disease, Parkinson's disease, dementia, multiple sclerosis, progressive supranuclear palsy (PSP) and depression. | The product SIRGT51321WQ-2OMe is a type of small interfering RNA (siRNA) that targets SYT8 gene and regulates the expression of gene. The siRNA interferes with the expression of SYT8 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNAThe product SIRGT51321WQ-2OMe is a type of small interfering RNA (siRNA) that targets SYT8 gene and regulates the expression of gene. The siRNA interferes with the expression of SYT8 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2_-O-methyl (2'-OMe) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More | The product SIRGT02109WQ-2F is a type of small interfering RNA (siRNA) that targets AP2A1 gene and regulates the expression of gene. The siRNA interferes with the expression of AP2A1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNAThe product SIRGT02109WQ-2F is a type of small interfering RNA (siRNA) that targets AP2A1 gene and regulates the expression of gene. The siRNA interferes with the expression of AP2A1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2_-deoxy-2_-fluoro (2'-F) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |